LONDON (Alliance News) - ReNeuron Group PLC said Tuesday that a paper detailing the efficiency of its human retinal stem cells in a test model of retinal degeneration had been published in the Journal of Biological Chemistry.
The test showed that ReNeuron's cells protected visual function when transplanted into the Royal College of Surgeons' rat model of retinal degeneration.
Eyes grafted with the cells showed superior visual acuity compared to untreated eyes, and showed a greater preservation of the outer nuclear layer of the retina in the treated animals.
"We are pleased to see this clear demonstration of the clinical potential of our human retinal progenitor cells in this newly published study using a well-validated model of retinal degeneration," said Chief Scientific Officer John Sinden in a statement.
The company is completing late pre-clinical development of its ReN003 therapy programme using the calls to target inherited, blindness causing disease retinitis pigmentosa.
Shares in ReNeuron were trading up 0.5% at 3.14 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)